2016
Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model
Siefert AL, Ehrlich A, Corral MJ, Goldsmith-Pestana K, McMahon-Pratt D, Fahmy TM. Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model. Biomaterials 2016, 108: 168-176. PMID: 27636154, PMCID: PMC5049880, DOI: 10.1016/j.biomaterials.2016.09.004.Peer-Reviewed Original ResearchConceptsPathogen-associated molecular patternsAccumulation of MDSCsHyper-inflammatory responseOngoing immune responseCytokine IL-10Antigen-presenting cellsCurrent treatment strategiesInflammation-mediated diseasesLong treatment regimensSite of infectionNew World leishmaniasisCellular immunomodulationIL-17Suppressor cellsDendritic cellsIL-10Immunotherapeutic approachesChronic inflammationTreatment regimensIL-13Free CpGTreatment strategiesTherapeutic effectImmune responsePreclinical studiesThe Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection
Wetzel DM, Rhodes EL, Li S, McMahon-Pratt D, Koleske AJ. The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection. Journal Of Cell Science 2016, 129: 3130-3143. PMID: 27358479, PMCID: PMC5004897, DOI: 10.1242/jcs.185595.Peer-Reviewed Original ResearchMeSH KeywordsAniline CompoundsAnimalsCytokinesDisease Models, AnimalImatinib MesylateImmunoglobulin GLeishmaniaLeishmaniasisMacrophagesMiceModels, BiologicalNitrilesParasitesPhagocytosisPhosphorylationProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-hckPyrimidinesQuinolinesRAW 264.7 CellsSignal TransductionSrc-Family KinasesConceptsAmastigote uptakeObligate intracellular parasite LeishmaniaImmunoglobulin-mediated phagocytosisIntracellular parasite LeishmaniaNovel therapeutic strategiesPersistence of infectionLeishmania infectionIgG-mediated phagocytosisTherapeutic strategiesFc receptorsSmall molecule inhibitorsArg activationDisease severityParasite burdenPrimary macrophagesMacrophagesKinase inhibitorsLeishmaniasisHuman hostDevastating diseaseInfectionParasite LeishmaniaSrc family kinasesPhagocytosisLeishmania
2012
The Abl and Arg Kinases Mediate Distinct Modes of Phagocytosis and Are Required for Maximal Leishmania Infection
Wetzel DM, McMahon-Pratt D, Koleske AJ. The Abl and Arg Kinases Mediate Distinct Modes of Phagocytosis and Are Required for Maximal Leishmania Infection. Molecular And Cellular Biology 2012, 32: 3176-3186. PMID: 22665498, PMCID: PMC3434515, DOI: 10.1128/mcb.00086-12.Peer-Reviewed Original ResearchConceptsComplement receptor 3Leishmania infectionIgG-coated beadsMurine cutaneous leishmaniasisPotential therapeutic targetLeishmania uptakeVisceral diseaseObligate intracellular parasitesCutaneous leishmaniasisTherapeutic targetFc receptorsAmastigote uptakeTreatment resultsReceptor 3Small lesionsInfection severityLeishmania amazonensisKinase inhibitorsIntracellular parasitesBead phagocytosisPhagocytosisReceptorsC3biInfectionLeishmaniasis
2011
TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia)
Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D. TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia). PLOS Neglected Tropical Diseases 2011, 5: e1204. PMID: 21695103, PMCID: PMC3114751, DOI: 10.1371/journal.pntd.0001204.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDisease Models, AnimalFemaleGenetic VectorsImmunization, SecondaryInterferon-gammaInterleukin-10Interleukin-13LeishmaniaLeishmaniasisLeishmaniasis VaccinesMiceMice, Inbred BALB CPeroxidasesProtozoan ProteinsRodent DiseasesToll-Like Receptor 1Toll-Like Receptor 2VaccinationVaccines, DNAVaccines, SyntheticVaccinia virusViral VaccinesConceptsPrime-boost vaccinationHeterologous prime-boost vaccinationCD8 T cellsT cell responsesT cellsTLR1/2 activationIL-10Vaccination modalityIL-13Immune responseAntigen-specific CD8 cellsCD8 T cell responsesCell responsesL. panamensis infectionsSpecific CD8 cellsTLR1/2 agonist Pam3CSK4IL-10 responsesVaccine-induced protectionCD4 T cellsMurine immune responseIL-13 responsesLeishmania speciesInfection/diseaseVaccinia virus AnkaraInnate immune response
2008
Intradermal NKT cell activation during DNA priming in heterologous prime‐boost vaccination enhances T cell responses and protection against Leishmania
Dondji B, Deak E, Goldsmith‐Pestana K, Perez‐Jimenez E, Esteban M, Miyake S, Yamamura T, McMahon‐Pratt D. Intradermal NKT cell activation during DNA priming in heterologous prime‐boost vaccination enhances T cell responses and protection against Leishmania. European Journal Of Immunology 2008, 38: 706-719. PMID: 18286565, PMCID: PMC3448375, DOI: 10.1002/eji.200737660.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibody FormationAntigens, ProtozoanCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesGalactosylceramidesGenetic VectorsGranzymesImmunity, CellularInterferon-gammaInterleukin-10Killer Cells, NaturalLeishmaniasisLymphocyte ActivationLymphocyte DepletionMiceMice, Inbred BALB CMice, Mutant StrainsNitric OxideProtozoan ProteinsSkinT-LymphocytesVaccinationVaccines, DNAVaccinia virusConceptsHeterologous prime-boost vaccinationPrime-boost vaccinationNKT cell activationCD8 T cellsT cellsCell activationVaccinated miceDNA primingActivated C-kinase (rLACK) antigensT cell immune responsesDevelopment of CD4Murine cutaneous leishmaniasisT cell responsesCell immune responsesElicit protective immunityIL-10Protective immunityImmune responseLeishmania homologueIFN-gammaAlphaGalCerCutaneous leishmaniasisVisceral leishmaniasisParasite burdenCell responses
2004
Leishmanial Amastigote Antigen P‐2 Induces Major Histocompatibility Complex Class II‐Dependent Natural Killer‐Cell Reactivity in Cells from Healthy Donors
Nylén S, Maasho K, McMahon‐Pratt D, Akuffo H. Leishmanial Amastigote Antigen P‐2 Induces Major Histocompatibility Complex Class II‐Dependent Natural Killer‐Cell Reactivity in Cells from Healthy Donors. Scandinavian Journal Of Immunology 2004, 59: 294-304. PMID: 15030581, DOI: 10.1111/j.0300-9475.2004.01388.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, ProtozoanCD8-Positive T-LymphocytesFetal BloodHistocompatibility Antigens Class IIHumansInterferon-gammaInterleukin-10Killer Cells, NaturalLeishmaniaLeishmaniasisLymphocyte ActivationProtozoan VaccinesReceptors, IgGReverse Transcriptase Polymerase Chain ReactionRNA, MessengerConceptsHealthy donorsLeishmaniasis patientsAmerican cutaneous leishmaniasis patientsClass IIMajor histocompatibility complex class IIMajor histocompatibility complex classHistocompatibility complex class IIClass II antibodiesCutaneous leishmaniasis patientsInterleukin-10 productionNatural killer cellsProtective immune responseInterferon-gamma productionIFN-gamma responsesMHC class IIHistocompatibility complex classHealthy adult donorsDevelopment of vaccinesAdherent cell populationAmastigote antigensNatural killerKiller cellsCytokine productionCell reactivityLeishmania infection
2002
Heterogeneity, geographic distribution, and pathogenicity of serodemes of Leishmania viannia in Colombia.
Saravia NG, Weigle K, Navas C, Segura I, Valderrama L, Valencia AZ, Escorcia B, McMahon-Pratt D. Heterogeneity, geographic distribution, and pathogenicity of serodemes of Leishmania viannia in Colombia. American Journal Of Tropical Medicine And Hygiene 2002, 66: 738-44. PMID: 12224583, DOI: 10.4269/ajtmh.2002.66.738.Peer-Reviewed Original Research
2001
Cellular trafficking in trypanosomatids: a new target for therapies?
Costa-Pinto D, Trindade L, McMahon-Pratt D, Traub-Cseko Y. Cellular trafficking in trypanosomatids: a new target for therapies? International Journal For Parasitology 2001, 31: 537-544. PMID: 11334939, DOI: 10.1016/s0020-7519(01)00145-x.Peer-Reviewed Original ResearchConceptsPathogenic trypanosomatidsTrafficking mechanismsLysosomal targetingCellular trafficking mechanismsPlethora of diseasesCellular traffickingTrypanosomatidsTargeting mechanismCysteine proteinasesBiological aspectsNew targetsCurrent knowledgeEfficient vaccineDisease controlTherapyBasic mechanismsTraffickingMechanismTargetParasitesVaccineProteinasesDiseaseTargeting
1991
Biochemical and molecular characterization ofLeishmania pifanoi amastigotes in continuous axenic culture
Rainey P, Spithill T, McMahon-Pratt D, Pan A. Biochemical and molecular characterization ofLeishmania pifanoi amastigotes in continuous axenic culture. Molecular And Biochemical Parasitology 1991, 49: 111-118. PMID: 1775152, DOI: 10.1016/0166-6851(91)90134-r.Peer-Reviewed Original ResearchConceptsContinuous axenic cultureSynthesis of DNAMolecular geneticsAdenine deaminaseAmastigote-like formsAxenic cultureAxenic mediumExcellent modelAxenic formsLeishmania pifanoiMetabolism of glucosePeroxidase activityAmastigote formsPromastigote formsAmastigotesCulture formsGenesGeneticsRNAProteinDNAReductaseRibonucleaseLinoleic acidPrevious demonstrationCharacterization of Leishmania colombiensis sp. n (Kinetoplastida: Trypanosomatidae), a new parasite infecting humans, animals, and phlebotomine sand flies in Colombia and Panama.
Kreutzer R, Corredor A, Grimaldi G, Grogl M, Rowton E, Young D, Morales A, McMahon-Pratt D, Guzman H, Tesh R. Characterization of Leishmania colombiensis sp. n (Kinetoplastida: Trypanosomatidae), a new parasite infecting humans, animals, and phlebotomine sand flies in Colombia and Panama. American Journal Of Tropical Medicine And Hygiene 1991, 44: 662-75. PMID: 1677544, DOI: 10.4269/ajtmh.1991.44.662.Peer-Reviewed Original ResearchConceptsNew parasiteRestriction endonuclease fragment patternsPhlebotomine sand fliesKinetoplast DNASand fliesFragment patternsMolecular criteriaNew memberL. braziliensis complexL. lainsoniSpFliesBraziliensis complexPanamaParasitesIsoenzyme electrophoresisGenusMonoclonal antibodiesDNAMembersSlothsCharacterizationElectrophoresisLainsoniIsolatesCharacterization and classification of leishmanial parasites from humans, wild mammals, and sand flies in the Amazon region of Brazil.
Grimaldi G, Momen H, Naiff R, McMahon-Pratt D, Barrett T. Characterization and classification of leishmanial parasites from humans, wild mammals, and sand flies in the Amazon region of Brazil. American Journal Of Tropical Medicine And Hygiene 1991, 44: 645-61. PMID: 1858968, DOI: 10.4269/ajtmh.1991.44.645.Peer-Reviewed Original ResearchLeishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease.
Barral A, Pedral-Sampaio D, Grimaldi G, Momen H, McMahon-Pratt D, de Jesus A, Almeida R, Badaro R, Barral-Netto M, Carvalho E, Johnson W. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. American Journal Of Tropical Medicine And Hygiene 1991, 44: 536-46. PMID: 2063957, DOI: 10.4269/ajtmh.1991.44.536.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrazilHumansLeishmaniaLeishmania braziliensisLeishmaniasisLeishmaniasis, MucocutaneousLeishmaniasis, VisceralConceptsMucocutaneous leishmaniasisCutaneous leishmaniasisClinical presentationVisceral leishmaniasisCases of CLMonoclonal antibodiesLeishmania amazonensisCases of DCLL. amazonensis infectionDifferent clinical presentationsDifferent clinical formsDifferent Leishmania speciesAmazonensis infectionClinical groundsIndistinguishable clinical presentationDermal leishmaniasisSpecific monoclonal antibodiesClinical formsClinical diseaseLeishmanial diseaseL. chagasiWide spectrumLeishmania referenceLeishmaniasisL. amazonensisLeishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras
Ponce C, Ponce E, Morrison A, Cruz A, Kreutzer R, McMahon-Pratt D, Neva F. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. The Lancet 1991, 337: 67-70. PMID: 1670724, DOI: 10.1016/0140-6736(91)90734-7.Peer-Reviewed Original ResearchConceptsCutaneous leishmaniasisSkin lesionsEndemic visceral leishmaniasisMontenegro skin testNew clinical variantAtypical cutaneous leishmaniasisSkin testLaboratory criteriaClinical variantsVisceral leishmaniasisKala-azarBone marrowPatientsParasite isolatesLesionsMajor antigenLeishmaniasisLeishmania mexicanaUnusual formIsoenzyme analysisYearsMarrowAntigenChagasiMonths
1989
A review of the geographic distribution and epidemiology of leishmaniasis in the New World.
Grimaldi G, Tesh R, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. American Journal Of Tropical Medicine And Hygiene 1989, 41: 687-725. PMID: 2701633, DOI: 10.4269/ajtmh.1989.41.687.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsCentral AmericaHumansLeishmaniaLeishmaniasisNorth AmericaSouth AmericaWest Indies
1988
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infection And Immunity 1988, 56: 3272-3279. PMID: 3182080, PMCID: PMC259734, DOI: 10.1128/iai.56.12.3272-3279.1988.Peer-Reviewed Original ResearchConceptsMouse strainsComplete protectionBALB/c strainLeishmania amazonensis infectionT cell immunityProtective immune responseOnset of infectionC. parvumAmazonensis infectionInfecting doseProtective immunityChallenge infectionC57BL/6 miceAntibody responseCBA miceComplete adjuvantEffective adjuvantImmune responseImmunized animalsLog phase promastigotesLevel of protectionL. amazonensisInfectionC strainLeishmania amazonensis
1985
Brazilian Leishmania stocks phenotypically similar to Leishmania major.
Momen H, Pacheco R, Jaffe C, Grimaldi G, Marzochi M, McMahon-Pratt D. Brazilian Leishmania stocks phenotypically similar to Leishmania major. American Journal Of Tropical Medicine And Hygiene 1985, 34: 1076-84. PMID: 3834794, DOI: 10.4269/ajtmh.1985.34.1076.Peer-Reviewed Original ResearchConceptsEnzyme profilesEnzyme electrophoresisL. mexicanaRestriction enzyme profilesL. donovani speciesIndirect radioimmuneNew World LeishmaniaL. braziliensisSchizodeme analysisL. majorMonoclonal antibodiesCutaneous speciesReference strainsSpeciesDifferent geographic areasMexicanaL. donovaniElectrophoresisLeishmaniaLarge panelSubspeciesBspRIMspIBraziliensisGeographic areas
1983
Monoclonal antibodies specific for Leishmania tropica. I. Characterization of antigens associated with stage- and species-specific determinants.
Jaffe C, McMahon-Pratt D. Monoclonal antibodies specific for Leishmania tropica. I. Characterization of antigens associated with stage- and species-specific determinants. The Journal Of Immunology 1983, 131: 1987-93. PMID: 6194223, DOI: 10.4049/jimmunol.131.4.1987.Peer-Reviewed Original ResearchConceptsSpecies-specific determinantsPromastigote stageDifferent cell surface proteinsCell surface proteinsMonoclonal antibody bindsMembrane-enriched preparationsCell surface componentsL. tropica complexAdditional proteinsKilodalton proteinClone TTrypanosoma cruziSurface proteinsProteinMonoclonal antibodiesIntact promastigotesSurface componentsSolubilized 125IL. donovaniL. braziliensis braziliensisMajor promastigotesL. mexicana amazonensisPromastigotesI. CharacterizationCruziIn vivo protection against Leishmania mexicana mediated by monoclonal antibodies.
Anderson S, David J, McMahon-Pratt D. In vivo protection against Leishmania mexicana mediated by monoclonal antibodies. The Journal Of Immunology 1983, 131: 1616-8. PMID: 6619540, DOI: 10.4049/jimmunol.131.4.1616.Peer-Reviewed Original Research